CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: March-15-08
Credit Expiration Date: March-31-09


Michael S. Blaiss, MD
Clinical Professor of Pediatrics & Medicine
University of Tennessee Health Services Center
Memphis, Tennessee

Eli O. Meltzer, MD
Clinical Professor of Pediatrics
University of California at San Diego
San Diego, California

Credit Hours

Physician CME: 1.0
Nursing CE: 1.0


Podcast (MP3 & PDF)

Program Description

This recording is a capture of a satellite symposium was originally presented January 22, 2007, at the 46th annual meeting of the Western Society of Asthma, Allergy & Immunology (WSAAI). The program is also available as an online program. If you received credit by attending the live symposium or by viewing the online version, you are not eligible to apply for credit through this podcast.

Conjunctivitis and asthma are two of the more common non-nasal comorbidities associated with rhinitis. Whether experienced as mild or severe, these comorbidities can seriously affect quality of life and productivity for patients and they make management more complicated for clinicians. With the rising prevalence of rhinitis, clinicians will face ever-increasing questions about the long-term efficacy and safety of rhinitis medications. Issues of noncompliance by patients and trivialization of rhinitis by many in the healthcare arena also contribute to an ever larger under-diagnosed and undertreated population.

Program Developer/Facilitator


Target Audience

This educational activity is designed to meet the needs of interested nurses as well as physicians specializing in allergy and immunology, ophthalmologists, and physicians in family medicine, pediatrics, and internal medicine.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the comorbidities of conjunctivitis and asthma associated with rhinitis and how they affect quality of life for patients and treatment decisions by clinicians.
  2. Evaluate effective pharmacologic strategies for managing rhinitis-conjunctivitis and rhinitis-asthma.
  3. Summarize the role of intranasal steroids, antihistamines, and other agents when treating patients with complex symptoms associated with rhinitis.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.

This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Blaiss discloses speakers' bureau service and advisory committee participation for Alcon, AstraZeneca, GlaxoSmithKline, Inspire, Merck, Sanofi-Aventis, Schering-Plough, and Teva. He previously owned stock in Schering-Plough.

Dr. Meltzer discloses speakers' bureau service for Alcon, Altana, AstraZeneca, Genentech, Genesis, GlaxoSmithKline, MedPointe, Merck, Pfizer, Sanofi-Aventis, Schering-Plough, and Verus. He has also served as a consultant for Abbott, Adelphi, Alcon, Allux, Amgen, AstraZeneca, Capnia, Critical Therapeutics, Dey, Evolutec, Genentech, GlaxoSmithKline, Greer, Inspire, KOS, MedPointe, Merck, Novartis, Nycomed (Altana), Pfizer, Rigel, Sanofi-Aventis, Schering-Plough, Shionogi, Verus, and Wyeth. He discloses receiving grant/research support from Alcon, Allux, AstraZeneca, Boehringer Ingelheim, Capnia, Clay-Park, Critical Therapeutics, Genentech, GlaxoSmithKline, Hoffmann-LaRoche, KOS, Medicinova, MedPointe, Merck, Novartis, Nycomed (Altana), Pharmaxis, Rigel, Sanofi-Aventis, Schering-Plough, Teva, and Wyeth.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
AKH designates this educational activity for 1.0 contact hour (0.1 CEU).

Commercial Support Statements

Supported through an educational grant from Schering-Plough Corporation.


This program consists of a Podcast/MP3 audio file and a printable PDF of the slides, which the learner can use to follow along, and a post-test that can be submitted for credit. You may play the audio online or download the file to an MP3 audio player, such as an iPod. You will also need Adobe Acrobat Reader to view and print the PDF.

  1. Click on the "Start program" icon. This will bring you to the login/registration page where you can register as a member if you have not already done so, or can check/revise existing registration information.
  2. Update your existing registration information, if necessary. When ready, click on the "Continue to Program" icon at the top or bottom of the screen. This will take you to the podcast description page for CMEcorner2go.
  3. Save the PDF file to your computer or open the file using the Adobe Acrobat Reader. Print a copy of the PDF, which includes the post-test and program evaluation. This can be used as a learning aid to follow along with the slides while you listen to the audio file.
  4. Download or play the audio file by clicking on the appropriate button. Instructions for utilizing this program on a portable MP3 player such as an iPod can be found on this page.
  5. Listen to the presentation before completing the post-test and evaluation. It should take approximately 60 minutes to listen to the audio and complete the post-test and evaluation.
  6. To receive CME/CE credit, follow the link to the post-test. A CME/CE statement will be awarded for a post-test score of 70% or better and by completing the evaluation. Successful completion of the post-test and evaluation online will enable you to immediately print a statement of credit. Alternately, complete by hand the post-test and evaluation found on the last two pages of the PDF. Mail or fax both pages according to the printed instructions. A CME/CE statement will be awarded for a post-test score of 70% or better and by completing the evaluation. A certificate will be mailed within 6 weeks.
  7. This CME/CE activity is available at, and through iTunes. Submit the post-test only once for this activity to receive credit. Multiple statements will not be issued.

Certificate Fee



©2008 Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the audio recording are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., WSAAI, or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu